BioNTech tests new cancer drug in First-Ever human trial
NCT ID NCT07455734
Summary
This is the first time the experimental drug BNT3214 will be given to people. The study aims to find a safe dose and see if it can help adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will test different dose levels and schedules, then expand to test the most promising doses in specific cancer types.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.